PGLFirst - Hereditary PGL/PCC Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Capillary (Sanger) Ambry Genetics Corp, Ambry Genetics - Aliso Viejo, CA, USA |
MAX Gene Sequence and Deletion/Duplication Analysis method(s): ◦ Sequencing, Capillary (Sanger) Ambry Genetics Corp, Ambry Genetics - Aliso Viejo, CA, USA |
MAX-Related Hereditary Paraganglioma-Pheochromocytoma Syndrome Test method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Capillary (Sanger) LabPLUS - Auckland City Hospital, Molecular Genetics Laboratory - Diagnostics Genetics - Auckland, New Zealand |
Hereditary Paraganglioma-Pheochromocytoma Syndrome Panel Test method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Capillary (Sanger) LabPLUS - Auckland City Hospital, Molecular Genetics Laboratory - Diagnostics Genetics - Auckland, New Zealand |
Hereditary PCC-PGL Panel (Sequence and deletion/duplication analysis) method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Capillary (Sanger) Children's Hospital of Philadelphia, Division of Genomic Diagnostics - Philadelphia, PA, USA |
Hereditary Pheochromocytoma (MAX sequence analysis) method(s): ◦ Sequencing, Capillary (Sanger) Children's Hospital of Philadelphia, Division of Genomic Diagnostics - Philadelphia, PA, USA |
Hereditary Cancer Syndrome: Sequencing Panel method(s): Emory University School of Medicine, Emory Molecular Genetics Laboratory - Atlanta, GA, USA |
NGS of 7 genes: KIF1B, MAX, RET, SDHAF2, SDHB, TMEM127, VHL method(s): ◦ Mutation Scanning of Entire Coding Region ◦ Sequencing, Next Gen Sistemas Genomicos, Medical Genetics Unit - Paterna, Spain |
PCC Syndrome method(s): ◦ Sequencing, Capillary (Sanger) Cologne University, Institute of Human Genetics - Cologne, Germany |
Hereditary Cancer Panel 170 PLUS method(s): ◦ Sequencing, Next Gen Genomic Laboratory of the DNA Research Center LTD (Centrum Badań DNA sp z o.o.) - Poznań, Poland |
Oncology Genetic Panel , Panel Massive Sequencing (NGS) 94 Genes method(s): ◦ Sequencing, Next Gen Reference Laboratory Genetics - Hospitalet de Llobregat, Spain |
Hereditary Pheochromocytoma-Paraganglioma Syndrome , Panel Massive Sequencing (NGS) 11 Genes method(s): ◦ Sequencing, Next Gen Reference Laboratory Genetics - Hospitalet de Llobregat, Spain |
CancerNext - Expanded method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Ambry Genetics Corp, Ambry Genetics - Aliso Viejo, CA, USA |
PGLNext - Hereditary PGL/PCC Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Ambry Genetics Corp, Ambry Genetics - Aliso Viejo, CA, USA |
Oncology, Panel method(s): ◦ Sequencing, Next Gen GENETAQ, Molecular Genetics Centre - Malaga, Spain |
Paraganglioma-Pheochromocytoma method(s): ◦ Sequencing, Next Gen GENETAQ, Molecular Genetics Centre - Malaga, Spain |
Hereditary Pheochromocytoma-Paraganglioma Syndrome, Sequencing MAX Gene method(s): ◦ Sequencing, Capillary (Sanger) Reference Laboratory Genetics - Hospitalet de Llobregat, Spain |
Hereditary Pheochromocytoma and Paraganglioma Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen University of Chicago, Genetic Services Laboratory - Chicago, IL, USA |
Hereditary Cancer Syndromes, Comprehensive Diagnostics method(s): ◦ Sequencing, Next Gen MGZ München, Medizinisch Genetisches Zentrum München - München, Germany |
Gastrointestinal Stromal Tumor method(s): ◦ Sequencing, Next Gen MGZ München, Medizinisch Genetisches Zentrum München - München, Germany |
Pheochromozytoma-Paraganglioma syndrome method(s): ◦ Sequencing, Next Gen MGZ München, Medizinisch Genetisches Zentrum München - München, Germany |
MAX method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Capillary (Sanger) ◦ Sequencing, Next Gen MGZ München, Medizinisch Genetisches Zentrum München - München, Germany |
Pheochromocytoma and Paraganglioma Panel method(s): ◦ Sequencing, Next Gen CeGaT GmbH - Tübingen, Germany |
Cancer Panel, Hereditary, Sequencing 46 Genes, Deletion/Duplication, 47 Genes method(s): ◦ Microarray (CGH-Oligo, SNP, BAC) ◦ Sequencing, Next Gen ARUP Laboratories, Molecular Genetics Laboratory - Salt Lake City, UT, USA |
Somatic Tumor Panel method(s): ◦ Sequencing, Next Gen CeGaT GmbH - Tübingen, Germany |
OncoRisk (NGS panel for 49 genes) method(s): ◦ Sequencing, Next Gen CGC Genetics - Porto, Portugal |
Pheochromocytoma (sequence analysis of MAX gene) method(s): ◦ Sequencing, Capillary (Sanger) CGC Genetics - Porto, Portugal |
Endocrine Cancer: Sequencing Panel method(s): ◦ Sequencing, Capillary (Sanger) ◦ Sequencing, Next Gen CEN4GEN Institute for Genomics and Molecular Diagnostics - Edmonton, Canada |
Endocrine Cancer: Deletion/Duplication Panel method(s): ◦ Del/Dup (CNV) CEN4GEN Institute for Genomics and Molecular Diagnostics - Edmonton, Canada |
Pheochromocytoma-Paraganglioma: Sequencing Panel method(s): ◦ Sequencing, Capillary (Sanger) ◦ Sequencing, Next Gen CEN4GEN Institute for Genomics and Molecular Diagnostics - Edmonton, Canada |
Pheochromocytoma-Paraganglioma: Deletion/Duplication Panel method(s): ◦ Del/Dup (CNV) CEN4GEN Institute for Genomics and Molecular Diagnostics - Edmonton, Canada |
OncoRisk Plus (NGS panel for 89 genes) method(s): ◦ Sequencing, Next Gen CGC Genetics - Porto, Portugal |
Cancer Predisposition method(s): ◦ Sequencing, Next Gen Asper Biotech Ltd., Asper Biotech - Tartu, Estonia |
PGL/PCC (Paraganglioma/Pheochromocytoma) Panel method(s): ◦ Microarray (CGH-Oligo, SNP, BAC) ◦ Sequencing, Next Gen GeneDx - Gaithersburg, MD, USA |
MAX method(s): ◦ Sequencing, Next Gen ◦ Sequencing, Capillary (Sanger) ◦ Del/Dup (CNV) Fulgent Diagnostics - Temple City, CA, USA |
Comprehensive Cancer Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Capillary (Sanger) ◦ Sequencing, Next Gen Fulgent Diagnostics - Temple City, CA, USA |
Paraganglioma-Pheochromocytoma Cancer Comprehensive Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Capillary (Sanger) ◦ Sequencing, Next Gen Fulgent Diagnostics - Temple City, CA, USA |
Comprehensive Hereditary Cancer Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen University of Chicago, Genetic Services Laboratory - Chicago, IL, USA |
CustomNext-Cancer method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Ambry Genetics Corp, Ambry Genetics - Aliso Viejo, CA, USA |
TAT: 3-4 weeks price: $690.00
Hereditary Paraganglioma-Pheochromocytoma Syndrome via the MAX Gene method(s): ◦ Del/Dup (CNV) PreventionGenetics (Prevention Genetics), Clinical DNA Testing and DNA Banking - Marshfield, WI, USA |
TAT: 3-4 weeks price: $1,290.00
Hereditary Paraganglioma-Pheochromocytoma Syndrome Deletion/Duplication Panel method(s): ◦ Del/Dup (CNV) PreventionGenetics (Prevention Genetics), Clinical DNA Testing and DNA Banking - Marshfield, WI, USA |
TAT: 2-3 weeks price: $610.00
Hereditary Paraganglioma-Pheochromocytoma Syndrome via the MAX Gene method(s): ◦ Sequencing, Capillary (Sanger) PreventionGenetics (Prevention Genetics), Clinical DNA Testing and DNA Banking - Marshfield, WI, USA |
TAT: 3-5 weeks price: $1,490.00
Hereditary Paraganglioma-Pheochromocytoma Syndrome Sequencing Panel method(s): ◦ Sequencing, Next Gen PreventionGenetics (Prevention Genetics), Clinical DNA Testing and DNA Banking - Marshfield, WI, USA |
Pheochromocytoma (Phäochromozytom) method(s): ◦ Sequencing, Next Gen Praxis fuer Humangenetik Wien - Vienna, Austria |
CEN4GEN Comprehensive Hereditary Cancer Syndrome: Sequencing Panel method(s): ◦ Sequencing, Next Gen CEN4GEN Institute for Genomics and Molecular Diagnostics - Edmonton, Canada |
Pheochromocytoma type 9 method(s): ◦ Sequencing, Capillary (Sanger) ◦ Del/Dup (CNV) Centogene AG, Rare Disease Company - Rostock, Germany |
Renal cell carcinoma method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Capillary (Sanger) Cologne University, Institute of Human Genetics - Cologne, Germany |
Paragangliomas method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Capillary (Sanger) Cologne University, Institute of Human Genetics - Cologne, Germany |
TAT: 1-3 weeks price: $1,500.00
Invitae Hereditary Paraganglioma-Pheochromocytoma Panel method(s): ◦ Sequencing, Next Gen ◦ Del/Dup (CNV) Invitae - San Francisco, CA, USA |
TAT: 1-3 weeks price: $1,500.00
Invitae Multi-Cancer Panel method(s): ◦ Sequencing, Next Gen ◦ Del/Dup (CNV) Invitae - San Francisco, CA, USA |
TAT: 1-3 weeks price: $1,500.00
Invitae Pediatric Solid Tumors Panel method(s): ◦ Sequencing, Next Gen ◦ Del/Dup (CNV) Invitae - San Francisco, CA, USA |
Multiple endocrine neoplasias/paraganglioma/pheochromocytoma panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Centogene AG, Rare Disease Company - Rostock, Germany |
Comprehensive Hereditary Cancer Panel method(s): ◦ Sequencing, Next Gen Baylor Miraca Genetics Laboratories - Houston, TX, USA |
Hereditary Endocrine Cancer Panel method(s): ◦ Sequencing, Next Gen Baylor Miraca Genetics Laboratories - Houston, TX, USA |
Hereditary Paraganglioma/Pheochromocytoma Panel method(s): ◦ Sequencing, Next Gen Baylor Miraca Genetics Laboratories - Houston, TX, USA |
Pheochromocytoma panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Centogene AG, Rare Disease Company - Rostock, Germany |
Comprehensive Hereditary Cancer Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Blueprint Genetics, Helsinki - Helsinki, Finland |
Hereditary Endocrine Cancer Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Blueprint Genetics, Helsinki - Helsinki, Finland |
Hereditary Paraganglioma-Pheochromocytoma Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Blueprint Genetics, Helsinki - Helsinki, Finland |
Hereditary Pediatric Cancer Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Blueprint Genetics, Helsinki - Helsinki, Finland |
Comprehensive Hereditary Cancer Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Blueprint Genetics, San Francisco - San Francisco, CA, USA |
Hereditary Endocrine Cancer Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Blueprint Genetics, San Francisco - San Francisco, CA, USA |
Hereditary Paraganglioma-Pheochromocytoma Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Blueprint Genetics, San Francisco - San Francisco, CA, USA |
Hereditary Pediatric Cancer Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Blueprint Genetics, San Francisco - San Francisco, CA, USA |
Phosphorus Pan Cancer Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Phosphorus Diagnostics - Livingston, NJ, USA |
Phosphorus Pediatric Cancers Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Phosphorus Diagnostics - Livingston, NJ, USA |
Phosphorus Brain and Nervous System Cancers Panel method(s): ◦ Del/Dup (CNV) ◦ Sequencing, Next Gen Phosphorus Diagnostics - Livingston, NJ, USA |